|
Apr 24
|
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
|
|
Apr 24
|
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
|
|
Apr 10
|
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
|
|
Mar 25
|
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
|
|
Mar 21
|
Capricor Therapeutics to Present at Upcoming Investor Conferences
|
|
Mar 14
|
Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
|
|
Mar 13
|
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
|
|
Mar 7
|
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
|
|
Mar 6
|
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
|
|
Feb 4
|
Market Sentiment Around Loss-Making Capricor Therapeutics, Inc. (NASDAQ:CAPR)
|
|
Sep 6
|
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
|
|
Jul 13
|
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
|